Abstract
Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have